Company Overview
Waldencast plc functions within the beauty and wellness industry, operating across the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand through two primary segments: Obagi Medical and Milk Makeup. The company focuses on offering skin care products designed to minimize signs of skin aging and address dark spots, positioning itself within the consumer defensive sector. As of the latest data, the entity maintains a market capitalization of $152.47M and employs 367 individuals to support its global operations. With an annual revenue of $272.07M, the company holds a market capitalization that reflects a mid-tier status within its industry, suggesting a firm that has established a significant presence but operates with a valuation characteristic of a smaller, specialized player rather than a large-cap blue-chip. This revenue figure, when viewed alongside the market cap, indicates a business model where the market assigns a lower multiple to sales, likely due to the company's current profitability challenges. The scale of 367 employees supports a diversified product portfolio that spans multiple international markets, allowing the company to leverage established distribution networks while navigating the complexities of a global regulatory environment.
Financial Health
The company reported total revenue of $272.07M over the trailing twelve months, yet it recorded a net income of $-229,748,992, creating a substantial gap that reveals a highly aggressive cost structure or significant non-operating expenses eroding bottom-line profitability. The EBITDA for the period stands at $-5,782,000, indicating that even before interest and taxes, the core operations are currently generating negative cash flow before financing costs. Despite the negative net income and EBITDA, the company generated free cash flow of $115.17M, which provides a critical layer of financial flexibility by demonstrating that operating activities can generate liquidity sufficient to cover capital expenditures and potentially service debt. The gross margin is reported at 67.3%, which is a healthy figure for the beauty industry, yet the operating margin of -22.5% and profit margin of -84.4% indicate that high fixed costs or one-time charges are severely compressing the bottom line. On the balance sheet, the company holds $30.38M in cash against $149.01M in debt, resulting in a debt-to-equity ratio of 29.80, which classifies the capital structure as highly leveraged and sensitive to interest rate fluctuations. The current ratio of 1.70 suggests that the company possesses 1.70 dollars of current assets for every dollar of current liabilities, indicating a reasonable ability to meet short-term obligations despite the leverage. Return on Equity is -40.3% and Return on Assets is -4.7%, metrics that collectively reveal that management is currently destroying value rather than generating returns on the capital deployed by shareholders and creditors.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the negative earnings, while the forward P/E is -2.41, a figure that implies the market is pricing in a specific trajectory of earnings recovery or continued losses in the coming year. The price-to-book ratio stands at 0.31, indicating that the stock is trading at a significant discount to its book value, which often suggests the market perceives significant intangible asset risks or expects a decline in future asset values. The price-to-sales ratio is 0.56 and the EV/EBITDA is -51.36, suggesting that valuation metrics relying on earnings are distorted by losses, forcing reliance on sales-based or enterprise value multiples that reflect the high risk associated with the current business model. The 52-week high is $3.34 and the 52-week low is $1.17; without a specific current share price provided in the facts, the valuation range indicates a stock that has experienced significant volatility and is currently trading well below its recent peak. The beta is -0.45, a unique and rare metric that suggests the stock price moves inversely to the broader market, offering a distinct risk profile that does not correlate positively with general market movements.
Growth & Income
Revenue growth year-over-year is -1.7%, while earnings growth is N/A due to the negative net income, implying that the company is currently contracting in terms of top-line sales rather than expanding its revenue base. Because the company is not a dividend payer, there is no dividend yield and the payout ratio is 0.0%, meaning the entity reinvests its limited earnings or utilizes its cash reserves to fund operations rather than returning capital to shareholders via dividends. The absence of a dividend yield combined with negative earnings growth highlights a growth and income profile focused entirely on operational turnaround rather than shareholder returns. The overall profile presents a high-risk scenario where the company is burning cash despite generating positive free cash flow, relying on market conditions or strategic pivots to reverse the negative revenue trend before any income generation can be realized.